Lv4
720 积分 2023-03-16 加入
Stereotactic Ablative Body Radiotherapy (SABR) for Oligoprogressive ER-Positive Breast Cancer (AVATAR): A Phase II Prospective Multicenter Trial
1个月前
已关闭
A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC)
3个月前
已完结
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
3个月前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
7个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
8个月前
已完结
Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer
8个月前
已完结
乳腺癌类器官在临床及转化应用中的进展
8个月前
已完结
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
9个月前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
9个月前
已完结
Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer
9个月前
已完结
皖公网安备34019202002308
